What Perdolan Enfant Treats: Main Uses and Benefits

A section that focuses on the therapeutic purpose of Perdolan Enfant is to offer supportive relief for symptomatic discomfort commonly experienced by pediatric patients. Its primary functions are centered on managing pain and fever, which is relevant for managing symptoms that interfere with daily comfort during illness. This medication is generally used to provide symptomatic relief and is used for managing elevated body temperature and mild-to-moderate physical pain.

It is commonly used to help with symptoms related to physical discomfort like headache, earache, sore throat pain, toothache, and general body aches that frequently accompany cold and flu syndromes. This application is relevant in conditions characterized by periods of heightened symptoms, such as common childhood infections or post-immunization reactions.

This supportive therapeutic benefit helps ease the overall symptom load, and may help patients cope more steadily with symptom fluctuations during the acute phase of illness.

---

Symptom Focus: Elevated Temperature and Acute Discomfort

Regulatory References

1. NIH MedlinePlus Medical Encyclopedia

Perdolan Enfant is a pain and fever relief medication intended for use in infants and children. The active ingredient is paracetamol (also known as acetaminophen). The appropriate formulation (e.g., syrup, suppositories) and dosage are determined by the child's age and body weight. Always consult the product's specific instructions for the minimum age and weight limits for the particular formulation you are using.

---

Contraindications and Precautions

Perdolan Enfant should not be used in children who have:

• A known allergy or hypersensitivity to paracetamol, phenacetin, or any other components of the specific drug formulation.
• Severe liver disease (hepatic impairment).
• Severe kidney disease (renal impairment).

Extreme caution and a medical consultation are necessary if the child is taking other medications, particularly those that also contain paracetamol, to prevent accidental overdose and subsequent liver damage. Parents and caregivers should ensure they do not exceed the maximum recommended daily dose and should seek medical advice if the child's fever or pain persists for more than three days.

Interactions with other medicines and products

Perdolan Enfant contains the active ingredient paracetamol (also known as acetaminophen). It is critical to avoid co-administration with any other medicine that contains paracetamol to prevent exceeding the maximum recommended dose and risking severe liver damage.

Potential Drug-Drug Interactions

Consult a healthcare professional if your child is taking any of the following medications, as a dose adjustment or increased monitoring may be required:

• Oral Anticoagulants (e.g., Warfarin): Regular or prolonged use of paracetamol can increase the effect of blood thinners, raising the risk of bleeding. Regular monitoring of the International Normalized Ratio (INR) is recommended.
• Enzyme-Inducing Drugs: Medicines such as phenytoin, phenobarbital, carbamazepine, primidone (used for epilepsy/seizures), rifampicin (used for tuberculosis), or isoniazid can increase the potential for liver toxicity when taken with paracetamol.
• Cholestyramine: This medication, used to lower cholesterol, can reduce the absorption and effectiveness of paracetamol if taken too closely together. A time interval between doses may be necessary.
• Probenecid: This gout medication can reduce the clearance of paracetamol, potentially requiring a dose reduction of Perdolan Enfant.
• Metoclopramide and Domperidone: These drugs, used for nausea and vomiting, can speed up the absorption of paracetamol, making it work faster.

Other Interactions

Paracetamol may also interfere with the results of certain laboratory tests, such as blood glucose level measurements and uric acid level measurements. Inform the laboratory personnel that your child has recently taken paracetamol before undergoing any diagnostic tests.

How Perdolan Enfant Works: Mechanism of Action

Central Modulation of Thermoregulation and Nociception

Perdolan Enfant acts by inhibiting the Cyclooxygenase (COX) enzyme system, particularly COX-2, primarily within the central nervous system (CNS). This molecular action blocks the conversion of arachidonic acid into prostaglandins (PGE2), the chemical mediators involved in signaling nociception and raising the thermoregulatory set point in the hypothalamus.

---

Selective Functional Targeting

The drug's mechanism demonstrates selective functional localization, concentrating its inhibition in the CNS pathways that govern temperature regulation and pain signaling. The central focus leads to the modulation of the thermoregulatory set point and nociceptive signaling. The drug exhibits minimal activity against peripheral inflammatory COX enzymes and maintains a lack of significant impact on platelet function.

How to Use Perdolan Enfant

The administration of Perdolan Enfant is governed by protocols designed for pediatric dosing, which emphasize precision and scheduled use. The medication is available for Oral administration (as liquid solution or syrup) and Rectal administration (as suppositories).

---

Official Dosing and Frequency

The dosing regimen is primarily based on the child's weight, with the standard individual dose calculated at 10 to 15 mg per kilogram (mg/kg) of body weight. The use is classified as intermittent and should adhere to a strict minimum interval of 4 to 6 hours between administrations. The total intake is capped at a maximum of 4 doses within any 24-hour period.

Administration Requirements

For oral suspensions, the product must be shaken well immediately prior to use to ensure uniform concentration. The dose must be measured precisely using the calibrated measuring device supplied with the product to maintain accuracy. The administration schedule is not dependent on mealtimes.

Population-Specific Use and Duration

Use is defined as short-term for symptomatic relief and should generally not exceed 3 days without consulting a healthcare professional. Specific guidelines apply to young infants: use in those under 3 months is often restricted by weight criteria or specific circumstances, such as post-immunisation pyrexia. Furthermore, patients with hepatic or severe renal impairment require adjustments, typically involving a reduction in the total daily dose or an extension of the dosing interval. A crucial instruction for correct use is the prohibition against simultaneous administration with any other paracetamol-containing product.

Research Evidence / Overview of Studies for Perdolan Enfant

This section outlines the structure of the scientific research that has observed paracetamol use, the active ingredient in Perdolan Enfant. It describes the types of studies conducted and what the resulting data contribute to the understanding of symptom patterns, without giving individual medical advice or making claims about guaranteed outcomes.

---

Evidence for Use in Managing Fever in Children

Research exploring short-term symptom changes, such as fever, primarily involves randomized controlled trials (RCTs), comparative trials, and systematic reviews. These short-term RCTs, often compared to an inactive substance (placebo) or another active medication like ibuprofen, was studied for how outcomes related to systemic or functional imbalance, specifically body temperature, are measured. Studies commonly focused on children from infancy through adolescence who experienced fever associated with common childhood illnesses.

Research highlights measurements recorded during the study period. Some studies reported patterns where temperature measurements changed during the observed interval following the administration of the study medication. These findings describe patterns observed in the studies and contribute to the broader evidence landscape related to temporary physiological imbalance in children.

Evidence for Use in Relieving Mild to Moderate Pain in Children

Scientific studies have explored the effect of paracetamol in research contexts involving fluctuating or unstable symptoms, such as mild to moderate pain. This research, often using short-term RCTs, focused on conditions associated with acute or disruptive episodes. Researchers monitored patient-reported outcomes describing perceived discomfort and other measurements reflecting daily functioning or activity level.

Studies describe patterns of reported pain scores in the observed populations. Research describes short-term changes in outcomes related to physical discomfort. Some trials described the time interval related to when changes in pain scores were first recorded. This research helps contextualize how patients reported their experience during the study period.

Overview of Safety Patterns in Controlled Trials

Safety patterns are typically monitored during the same controlled trials that examine symptom patterns related to pain or fever. Researchers monitored outcomes related to physiological strain or stress by tracking the frequency and type of observed adverse events (AEs), serious adverse events (SAEs), and specific laboratory measurements, such as liver enzyme activity.

Studies reported various patterns of AEs occurring in children who was observed in the paracetamol groups compared to other groups. Some research describes a pattern of temporary, low-level changes in certain liver enzyme markers, although these specific findings were not consistently reported across all studies. This information helps contextualize how patients reported their experience during the short-term use evaluated in research.

Evidence Gaps and Uncertainties

Follow-up durations were limited in safety reporting, corresponding only to the duration of the acute pain or fever study. This means that data are still emerging regarding certain safety questions, and any potential long-term systemic patterns following exposure are not fully established.

Long-term effects are not fully established regarding the patterns of repeated paracetamol use for recurrent fever. Follow-up durations were limited in the majority of the existing trials. Additionally, the available data for certain specific subgroups, such as children with coexisting liver or metabolic conditions, remain insufficient.

Key Studies & References

1. Treating fever in children: paracetamol or ibuprofen? (Meta-analysis of RCTs)
2. MSF Medical Guidelines: PARACETAMOL = ACETAMINOPHEN oral (Clinical guidance and dosing reference)

Common questions about Perdolan Enfant (FAQ)

---

Q: Is Perdolan Enfant the same as other medicines containing paracetamol?

Perdolan Enfant contains paracetamol (also known as acetaminophen) as its active ingredient, which is chemically the same across all products using that substance. However, different brands may use distinct inactive ingredients (excipients) or come in different formulations, strengths, and formats. Official product information describes the full composition.

---

Q: Are there any common reasons people mistakenly use Perdolan Enfant?

A primary misuse concern highlighted in regulatory warnings is the co-administration of this product with any other medicine that already contains paracetamol. To mitigate the risk, health authorities emphasize strictly following the administration directions on the label.

---

Q: Is it normal for a child to feel a bit sleepy after taking this medicine?

Drowsiness or sleepiness is generally not consistently listed as a common effect when the medication is used properly within recommended limits. However, official safety information indicates that signs associated with overexposure to the active ingredient may include extreme sleepiness.

---

Q: Is Perdolan Enfant considered a non-steroidal anti-inflammatory drug (NSAID)?

No. The active ingredient in Perdolan Enfant is officially classified as an analgesic (pain reliever) and antipyretic (fever reducer). It is structurally and functionally distinct from the class of medicines known as non-steroidal anti-inflammatory drugs (NSAIDs).

---

Q: Does Perdolan Enfant treat inflammation, or just pain and fever?

Regulatory text describes the active ingredient’s primary actions as targeting the central systems that regulate body temperature and pain signaling. The mechanism of action is described as having minimal activity against peripheral inflammatory processes, meaning its main indications are for pain and fever reduction.

---

Q: What is the difference between Perdolan Enfant and an ibuprofen-based product?

Perdolan Enfant’s active ingredient is chemically different from ibuprofen, which is classified as an NSAID. The product profile is described as having specific regulatory differences, and it is frequently recommended for different patient populations.

---

Q: Are there known long-term side effects from using Perdolan Enfant occasionally?

Official documentation indicates that use of this medicine is defined as short-term for symptomatic relief and generally should not exceed three days without seeking professional medical advice. The follow-up duration in most clinical trials is limited, meaning that long-term systemic patterns from occasional use are not fully established in research.

---

Q: Is Perdolan Enfant a prescription-only medicine?

The active ingredient is widely available over-the-counter (OTC) without a prescription in many countries. However, regulatory bodies often place restrictions on the maximum package size that can be purchased, and some specific dosage formats may require sale under pharmacist supervision.

---

Q: Is there a difference in how the liquid and the suppositories work?

Studies comparing the different formulations indicate that the oral liquid suspension typically results in a faster onset of action. Fever reduction may reach its maximum effect earlier with the liquid formulation compared to the rectal suppositories.

---

Q: Why are there different strengths or formats of Perdolan Enfant?

Different strengths and formats, such as liquid and suppositories, are required to facilitate accurate, weight-based dosing across the wide range of pediatric ages. This differentiation helps to ensure that the appropriate amount of medicine can be administered reliably to children of various sizes.

---

Q: Are there any known allergic reactions to Perdolan Enfant?

Official regulatory warnings highlight the potential for severe allergic reactions (hypersensitivity) to the active ingredient. These reactions can include serious symptoms such as swelling of the face and throat, difficulty breathing, and rash.

---

Q: Can Perdolan Enfant be used for children who have had a vaccination?

Official guidelines in some jurisdictions explicitly mention that the active ingredient can be used for fever that occurs following routine childhood immunisations (known as post-immunisation pyrexia).

---

Q: Is Perdolan Enfant suitable for very young infants?

Official guidelines in certain countries allow for the use of the active ingredient in infants as young as two to three months of age, provided they meet specific criteria, such as weighing over 4 kg and being born after 37 weeks.

---

Q: Is there a specific age limit for use?

The minimum recommended age for general use of the active ingredient is typically three months and over. Specific circumstances, such as post-immunisation fever, may allow for restricted use in certain two to three-month-old infants, subject to professional guidance.

---

Q: Is it safe to give Perdolan Enfant at the same time as certain antibiotics?

The interaction profiles listed in regulatory documents are specific, and consultation is typically advised for concurrent use with any other medicine.

---

Q: Can Perdolan Enfant be used for teething pain?

Official guidance from government health services and authoritative medical institutions lists teething pain as one of the types of mild to moderate pain for which the active ingredient may be used.

---

Q: Does Perdolan Enfant contain gluten or sugar?

Medications contain various inactive ingredients (excipients). Information regarding the presence of specific components like gluten or sugar is typically found on the specific product's label or package leaflet, as current labeling rules do not universally require clear labeling of all such components.

---

Q: Can Perdolan Enfant be mixed with juice or milk?

Official guidance for oral liquid formulations sometimes mentions that the medicine can be mixed with a small amount of liquid or soft food. This is often suggested to help ensure the full amount of medicine is administered easily.

---

Q: What is the active ingredient's official safety classification?

The active ingredient in Perdolan Enfant, paracetamol (acetaminophen), is listed on the World Health Organization’s List of Essential Medicines. This indicates its importance in global public health and therapeutic value.

---

Q: Why is the active ingredient in Perdolan Enfant popular worldwide?

It is recommended by health bodies for the short-term relief of pain and fever and is included on the World Health Organization’s Essential Medicines List.

---

Q: Have there been any recent changes to the official warnings for Perdolan Enfant?

Regulatory bodies frequently review safety data and issue updates to product warnings. For example, the FDA previously updated warnings and limited the strength of the active ingredient in prescription products. Consumers are advised to check current safety alerts from relevant health authorities.

---

Q: Can Perdolan Enfant be used if a child has a minor scratch or bruise?

The drug is indicated for the temporary relief of mild to moderate pain. If a minor scratch or bruise results in a level of mild pain, the medicine is covered under this general indication.

--UNSURE

Q: Does the efficacy of Perdolan Enfant vary by weight or age group?

Achieving therapeutic efficacy is directly linked to administering a dose based on the child’s weight, typically 10 to 15 milligrams per kilogram. Additionally, regulatory information indicates that the rate at which the body processes the drug (clearance) changes with age, especially in children under three years old.

---

Q: Why do health authorities emphasize reading the label carefully for this medicine?

Health authorities emphasize careful label reading primarily to ensure the correct dose is measured and to strictly prohibit co-administering the drug with any other paracetamol-containing products. This is crucial for preventing the risk of exceeding the maximum recommended limit and causing potential liver damage.

---

Q: What are the official restrictions on who can purchase Perdolan Enfant?

Official regulations in some countries restrict the maximum quantity of the drug that can be purchased in a single transaction to mitigate the risk of overdose. These restrictions apply both in general retail settings and in pharmacies.

Storage and Disposal Requirements

The official storage and disposal guidelines for Perdolan Enfant are strictly defined in regulatory labeling to ensure product stability and safety. This medication must be stored at controlled room temperature, typically 20 C to 25 C, and away from environments that contain excess heat and moisture (such as a bathroom). It is mandatory to keep the product out of the sight and reach of children and to ensure the original container is tightly closed.

To maintain the quality of the medicine, it must also be protected from light. Regarding disposal, regulatory sources instruct that expired or unused medicine should not be flushed down the toilet or placed in household waste; a pharmaceutical take-back program is the recommended method for disposal.